Evidence map›Paper›PMID 38114048›Full record

ArticleNeurobiology of disease2024

Resting-state EEG signatures of Alzheimer's disease are driven by periodic but not aperiodic changes.

Martina Kopčanová, Luke Tait, Thomas Donoghue, George Stothart, Laura Smith, Aimee Arely Flores-Sandoval, Paula Davila-Perez, Stephanie Buss, Mouhsin M Shafi, Alvaro Pascual-Leone and 2 more

Open access · goldAbstract read
PubMed Publisher
In one paragraph

Article in Neurobiology of disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 3 pooled it
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 3 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. mTORC2-NaChannels (Austin, Tex.) · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Excitation-inhibition homeostasis in Alzheimer's disease: a selective multiscale review of mechanisms, sex differences, and therapeutic opportunities.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 4 countries.

Martina KopčanováDivision of Psychology, School of Humanities, Social Sciences and Law, University of Dundee, Dundee, UK. Electronic address: m.kopcanova@dundee.ac.uk.
Luke TaitCentre for Systems Modelling and Quantitative Biomedicine, School of Medical and Dental Sciences, University of Birmingham, UK; Cardiff University Brain Research Imaging Centre, Cardiff, UK.
Thomas DonoghueDepartment of Biomedical Engineering, Columbia University, New York, USA.
George StothartSchool of Psychology, University of Bath, Bath, UK.
Laura SmithWolfson Institute of Population Health, Queen Mary University of London, London, UK.
Aimee Arely Flores-SandovalCharité - Universitätsmedizin Berlin, Einstein Center for Neurosciences Berlin, 10117 Berlin, Germany; Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.
Paula Davila-PerezRey Juan Carlos University Hospital (HURJC), Department of Clinical Neurophysiology, Móstoles, Madrid, Spain; Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
Stephanie BussBerenson-Allen Center for Noninvasive Brain Stimulation, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA; Department of Neurology, Harvard Medical School, Boston, MA, USA.
Mouhsin M ShafiBerenson-Allen Center for Noninvasive Brain Stimulation, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA; Department of Neurology, Harvard Medical School, Boston, MA, USA.
Alvaro Pascual-LeoneDepartment of Neurology, Harvard Medical School, Boston, MA, USA; Hinda and Arthur Marcus Institute for Aging Research and Deanna and Sidney Wolk Center for Memory Health, Hebrew SeniorLife, Boston, MA, United States of America.
Peter J FriedBerenson-Allen Center for Noninvasive Brain Stimulation, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA; Department of Neurology, Harvard Medical School, Boston, MA, USA.
Christopher S Y BenwellDivision of Psychology, School of Humanities, Social Sciences and Law, University of Dundee, Dundee, UK.
Harvard University · USUniversity of Dundee · GBBerenson Allen Center for Noninvasive Brain Stimulation · USBeth Israel Deaconess Medical Center · USCardiff University · GBColumbia University · USMax Planck Institute for Human Cognitive and Brain Sciences · DEQueen Mary University of London · GBUniversidad Autónoma de Madrid · ESUniversity of Bath · GB

Funding

The Role of Inflammation in the Pathophysiology of Delirium and its Associated Long-Term Cognitive DeclineP01AG031720 · NIA · HEBREW REHABILITATION CENTER FOR AGED · PI INOUYE, SHARON K. · 2010 to 2022
$26.7M
Repetitive TMS-induced modulation of cortical excitability in ADR01MH115949 · NIMH · BETH ISRAEL DEACONESS MEDICAL CENTER · PI SHAFI, MOUHSIN · 2018 to 2022
$3.2M
Multifocal transcranial current stimulation for cognitive and motor dysfunction in dementiaR01AG076708 · NIA · HEBREW REHABILITATION CENTER FOR AGED · PI MANOR, BRADLEY D., PASCUAL-LEONE, ALVARO · 2022 to 2024
$2.3M
Understanding the structural, functional, and prognostic implications of cortical excitability in Alzheimer's diseaseK23AG068364 · NIA · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BUSS, STEPHANIE · 2021 to 2025
$921k
Cortical plasticity in type II diabetes mellitusR21NS082870 · NINDS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI PASCUAL-LEONE, ALVARO · 2013 to 2014
$490k
Brain Plasticity Measures in MCIR21AG051846 · NIA · BETH ISRAEL DEACONESS MEDICAL CENTER · PI PASCUAL-LEONE, ALVARO · 2016 to 2017
$476k
System biology approach to decode molecular mechanism of glucose metabolism in AD and dementiaR03AG072233 · NIA · HEBREW REHABILITATION CENTER FOR AGED · PI JEONG, SOHYUN · 2022 to 2023
$320k
NIA NIH HHS K23 AG068364NIA NIH HHS P01 AG031720NIA NIH HHS R01 AG076708NIA NIH HHS R03 AG072233NIA NIH HHS R21 AG051846NIMH NIH HHS R01 MH115949NINDS NIH HHS R21 NS082870
6 · The paper itself

Abstract

Electroencephalography (EEG) has shown potential for identifying early-stage biomarkers of neurocognitive dysfunction associated with dementia due to Alzheimer's disease (AD). A large body of evidence shows that, compared to healthy controls (HC), AD is associated with power increases in lower EEG frequencies (delta and theta) and decreases in higher frequencies (alpha and beta), together with slowing of the peak alpha frequency. However, the pathophysiological processes underlying these changes remain unclear. For instance, recent studies have shown that apparent shifts in EEG power from high to low frequencies can be driven either by frequency specific periodic power changes or rather by non-oscillatory (aperiodic) changes in the underlying 1/f slope of the power spectrum. Hence, to clarify the mechanism(s) underlying the EEG alterations associated with AD, it is necessary to account for both periodic and aperiodic characteristics of the EEG signal. Across two independent datasets, we examined whether resting-state EEG changes linked to AD reflect true oscillatory (periodic) changes, changes in the aperiodic (non-oscillatory) signal, or a combination of both. We found strong evidence that the alterations are purely periodic in nature, with decreases in oscillatory power at alpha and beta frequencies (AD < HC) leading to lower (alpha + beta) / (delta + theta) power ratios in AD. Aperiodic EEG features did not differ between AD and HC. By replicating the findings in two cohorts, we provide robust evidence for purely oscillatory pathophysiology in AD and against aperiodic EEG changes. We therefore clarify the alterations underlying the neural dynamics in AD and emphasize the robustness of oscillatory AD signatures, which may further be used as potential prognostic or interventional targets in future clinical investigations.

Indexed as

Alzheimer DiseaseCognitive DysfunctionBiomarkersElectroencephalographyHumansRestBiomarkersAlzheimer'sDementiaEEGOscillations

Identifiers

PMID38114048
OpenAlexW4389905782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.